1. Home
  2. ADCT vs NMAI Comparison

ADCT vs NMAI Comparison

Compare ADCT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.11

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Multi-Asset Income Fund of Beneficial Interest

NMAI

Nuveen Multi-Asset Income Fund of Beneficial Interest

HOLD

Current Price

$13.03

Market Cap

461.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADCT
NMAI
Founded
2011
2021
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
484.4M
461.6M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADCT
NMAI
Price
$4.11
$13.03
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$7.50
N/A
AVG Volume (30 Days)
812.5K
107.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
13.14%
EPS Growth
44.90
N/A
EPS
N/A
0.64
Revenue
$70,837,000.00
N/A
Revenue This Year
$14.96
N/A
Revenue Next Year
$1.06
N/A
P/E Ratio
N/A
$20.66
Revenue Growth
1.84
N/A
52 Week Low
$1.05
$10.21
52 Week High
$4.80
$13.96

Technical Indicators

Market Signals
Indicator
ADCT
NMAI
Relative Strength Index (RSI) 51.41 31.37
Support Level $3.25 $12.72
Resistance Level $4.71 $13.05
Average True Range (ATR) 0.25 0.18
MACD -0.02 -0.09
Stochastic Oscillator 29.76 6.82

Price Performance

Historical Comparison
ADCT
NMAI

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.

Share on Social Networks: